Shows increased antibody-drug conjugate efficacy in refractory solid tumors, suggesting a novel treatment strategy.
M2-like tumor-associated macrophages, whereas ADC-mediated bystander killing attenuated this adaptive feedback and promoted a more immunoactive tumor microenvironment. Together, these findings support LDRT as a clinically translatable strategy to increase ICAM1 expression, overcome antigen-low barriers, and enhance ADC efficacy in refractory solid tumors.
No takes yet. Share an insight, caveat, or question.
Xing et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: